These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 8462229)

  • 21. Kinetics of angiotensin-converting enzyme inhibitors in renal failure.
    Sica DA
    J Cardiovasc Pharmacol; 1992; 20 Suppl 10():S13-20. PubMed ID: 1283426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quinapril: a new second-generation ACE inhibitor.
    Cetnarowski-Cropp AB
    DICP; 1991 May; 25(5):499-504. PubMed ID: 2068835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease.
    Sica DA; Gehr TW; Fernandez A
    Drug Saf; 2000 May; 22(5):350-60. PubMed ID: 10830252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapy.
    Burnier M; Biollaz J
    Clin Pharmacokinet; 1992 May; 22(5):375-84. PubMed ID: 1505143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High serum enalaprilat in chronic renal failure.
    Elung-Jensen T; Heisterberg J; Kamper AL; Sonne J; Strandgaard S; Larsen NE
    J Renin Angiotensin Aldosterone Syst; 2001 Dec; 2(4):240-5. PubMed ID: 11881130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension.
    Petersen LJ; Petersen JR; Talleruphuus U; Møller ML; Ladefoged SD; Mehlsen J; Jensen HA
    Clin Nephrol; 2001 May; 55(5):375-83. PubMed ID: 11393383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency.
    Verpooten GA; Genissel PM; Thomas JR; De Broe ME
    Br J Clin Pharmacol; 1991 Aug; 32(2):187-92. PubMed ID: 1657092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin-converting enzyme inhibitors and renal function.
    Mason NA
    DICP; 1990 May; 24(5):496-505. PubMed ID: 2188438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Kidney function in hypertensive patients with chronic renal failure treated with the dual eliminated ACE-inhibitor spirapril].
    Haufe CC; Sierakowski B; Jansa U; Stein G
    Med Klin (Munich); 1994 Aug; 89(8):416-20. PubMed ID: 7968874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic advantages of angiotensin converting enzyme inhibitors in chronic renal disease.
    Omata K; Kanazawa M; Sato T; Abe F; Saito T; Abe K
    Kidney Int Suppl; 1996 Jun; 55():S57-62. PubMed ID: 8743512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ramipril: a review of the new ACE inhibitor.
    Mills TP
    J Ark Med Soc; 1992 Feb; 88(9):437-40. PubMed ID: 1532570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal or impaired renal function.
    Shionoiri H; Gotoh E; Sugimoto K; Takasaki I; Minamisawa K; Ishii M
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):283S-287S. PubMed ID: 2527540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection.
    Grover GJ; Sleph PG; Dzwonczyk S; Wang P; Fung W; Tobias D; Cushman DW
    J Pharmacol Exp Ther; 1991 Jun; 257(3):919-29. PubMed ID: 1646329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with chronic renal failure.
    Hoogkamer JF; Kleinbloesem CH; Nokhodian A; Ouwerkerk MJ; Lankhaar G; Ungethüm W; Kirch W
    Eur J Clin Pharmacol; 1998 Mar; 54(1):59-61. PubMed ID: 9591932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Therapy with ACE inhibitors in chronic heart failure and limited kidney function].
    Osterziel KJ; Nagel F; Dietz R
    Z Kardiol; 1994; 83 Suppl 4():81-7. PubMed ID: 7856286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics.
    Belz GG; Kirch W; Kleinbloesem CH
    Clin Pharmacokinet; 1988 Nov; 15(5):295-318. PubMed ID: 2849518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin-converting enzyme inhibitors in chronic renal failure.
    Opsahl JA; Abraham PA; Keane WF
    Drugs; 1990; 39 Suppl 2():23-32. PubMed ID: 2188823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Critical assessment of ACE inhibitors. Part 2.
    Howes LG
    Aust Fam Physician; 1995 Apr; 24(4):639, 641-3. PubMed ID: 7771972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.